Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5589 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-20

Study Completion Date

2019-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.

This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

NCT03572231

Overactive Bladder (OAB)

COMPLETED

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072

Urinary Bladder Overactive Overactive Bladder Urinary Bladder Diseases +1 more

COMPLETED

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

NCT05040984

Overactive Bladder Syndrome

UNKNOWN

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214

Overactive Bladder (OAB)

COMPLETED PHASE4

Predictors for Retreatement of OAB After DC Mirabegron

NCT04550702

Recurrence of Overactive Bladder Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is entirely descriptive using secondary medical claim and pharmacy prescription data. No formal comparisons between users of mirabegron and antimuscarinic will be made. Furthermore, no a priori hypothesis testing is intended.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder (OAB)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mirabegron

Patients on mirabegron as prescribed by a physician in routine clinical practice.

mirabegron

Intervention Type DRUG

oral

antimuscarinics

Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.

solifenacin

Intervention Type DRUG

oral

darifenacin

Intervention Type DRUG

oral

imidafenacin

Intervention Type DRUG

oral

tolterodine

Intervention Type DRUG

oral

oxybutynin

Intervention Type DRUG

oral

trospium

Intervention Type DRUG

oral

fesoterodine

Intervention Type DRUG

oral

propiverine

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mirabegron

oral

Intervention Type DRUG

solifenacin

oral

Intervention Type DRUG

darifenacin

oral

Intervention Type DRUG

imidafenacin

oral

Intervention Type DRUG

tolterodine

oral

Intervention Type DRUG

oxybutynin

oral

Intervention Type DRUG

trospium

oral

Intervention Type DRUG

fesoterodine

oral

Intervention Type DRUG

propiverine

oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

YM178 Betmiga YM905 Vesicare

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with a new prescription of the index medication within the index period;
* Patient received orally administered monotherapy for OAB on index date.

Exclusion Criteria

* Patient with prior dispensing record of the index medication during the pre-index period;
* Patient received onabotulinumtoxin A and/or surgical intervention as part of the OAB treatment between the pre index and post-index period;
* Patient diagnosed with stress incontinence (International Classification of Diseases-10 (ICD-10) N39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) before index date;
* Patient with urinary tract infection (ICD-10 N30.0 or equivalent) (for National Health Insurance Research Database (NHIRD) and Health Insurance Review and Assessment (HIRA) database) or a co-prescription of any antibiotics (for NostraData) on index date.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No